Clinical Trials
8 trialsNCT02681302 2026-04-03
CPIT001
Hackensack Meridian Health
Phase 1/2 Terminated
NCT02663518 2024-05-10
A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors
Pfizer
Phase 1 Terminated
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT04119336 2023-08-21
Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma
Massachusetts General Hospital
Phase 2 Terminated
NCT03782064 2023-06-22
Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma
Beth Israel Deaconess Medical Center
Phase 2 Terminated
NCT03634800 2021-08-05
RISE-M
Weill Medical College of Cornell University
Phase 2 Terminated
NCT03333746 2019-05-30
Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma
Ohio State University Comprehensive Cancer Center
Phase 2 Terminated
NCT03023527 2018-05-23
Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma
PETHEMA Foundation
Phase 1 Terminated